Arovella Therapeutics (ASX:ALA) appointed three "opinion leaders" and clinical oncologists to establish a clinical advisory board to provide strategic advice on CD19-positive hematological malignancies known as blood cancers, according to a Monday filing with the Australian bourse.

The move comes amid the biotech company's plan to file an investigational new drug application with the US Food and Drug Administration and launch its first-in-human phase 1 clinical trial, the filing stated.